Related Experiment Video
Updated: Nov 3, 2025
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Exploring the pathways to chronic lymphocytic leukemia
Freda K Stevenson1, Francesco Forconi1,2, Thomas J Kipps3
1School of Cancer Sciences, Cancer Research UK Southampton Centre, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Abstract:
In chronic lymphocytic leukemia (CLL), increasing knowledge of the biology of the tumor cells has led to transformative improvements in our capacity to assess and treat patients. The dependence of tumor cells on surface immunoglobulin receptor signaling, survival pathways, and accessory cells within the microenvironment has led to a successful double-barreled attack with designer drugs. Studies have revealed that CLL should be classified based on the mutational status of the expressed IGHV sequences into 2 diseases, either unmutated (U) or mutated (M) CLL, each with a distinctive cellular origin, biology, epigenetics/genetics, and clinical behavior. The origin of U-CLL lies among the natural antibody repertoire, and dominance of IGHV1-69 reveals a superantigenic driver. In both U-CLL and M-CLL, a calibrated stimulation of tumor cells by self-antigens apparently generates a dynamic reiterative cycle as cells, protected from apoptosis, transit between blood and tissue sites. But there are differences in outcome, with the balance between proliferation and anergy favoring anergy in M-CLL. Responses are modulated by an array of microenvironmental interactions. Availability of T-cell help is a likely determinant of cell fate, the dependency on which varies between U-CLL and M-CLL, reflecting the different cells of origin, and affecting clinical behavior. Despite such advances, cell-escape strategies, Richter transformation, and immunosuppression remain as challenges, which only may be met by continued research into the biology of CLL.
Insights
Chronic lymphocytic leukemia (CLL) is now classified into mutated and unmutated types based on IGHV gene mutation status. This classification impacts treatment strategies and understanding of disease biology, though challenges remain.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by the accumulation of malignant lymphocytes.
- Advances in understanding CLL cell biology have improved patient assessment and treatment, particularly targeting surface immunoglobulin receptor signaling and survival pathways.
- CLL classification based on IGHV mutational status (mutated [M-CLL] vs. unmutated [U-CLL]) reveals distinct biological and clinical behaviors.
Purpose of the Study:
- To elucidate the distinct biological origins and clinical behaviors of mutated and unmutated CLL.
- To highlight the role of microenvironmental interactions and T-cell help in modulating CLL cell fate.
- To identify remaining challenges in CLL management, including therapeutic resistance and Richter transformation.
Main Methods:
- Classification of CLL based on IGHV sequence mutational status.
- Analysis of cellular origin, biology, epigenetics, genetics, and clinical behavior for M-CLL and U-CLL subtypes.
- Investigation of microenvironmental interactions and T-cell help in disease progression.
Main Results:
- U-CLL originates from the natural antibody repertoire, potentially driven by superantigens like IGHV1-69.
- Both M-CLL and U-CLL cells undergo cycles of proliferation and apoptosis evasion, influenced by self-antigen stimulation.
- M-CLL exhibits a greater tendency towards anergy compared to U-CLL, with T-cell help significantly impacting cell fate and clinical outcomes.
Conclusions:
- IGHV mutational status is a critical determinant of CLL biology and clinical behavior, necessitating distinct therapeutic approaches.
- Microenvironmental factors, especially T-cell interactions, play a crucial role in modulating CLL progression and response to therapy.
- Continued research into CLL biology is essential to overcome challenges such as therapeutic escape, Richter transformation, and immunosuppression.
More Related Videos
Related Concept Videos
01:23Cells of the Adaptive Immune Response
01:16Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
01:21Lineage Commitment
01:31The Intrinsic Apoptotic Pathway
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:18Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...